Laura Joszt, MA

A safety analysis of 6 trials found zanubrutinib has a toxicity profile consistent wth other Bruton tyrosine kinase (BTK) inhibitors.

The real-world visual acuity gains in age-related macular degeneration (AMD) after treatment have been inferior to those seen in clinical trials, explained a speaker during the American Academy of Ophthalmology 2021 meeting.

Patients with thyroid eye disease (TED) have high rates of health care resource utilization (HRU) and their disease has substantial impact on their quality of life (QOL).

An evaluation of data from the Global Burden of Disease found that nonalcoholic fatty liver disease (NAFLD) is a main driver of chronic liver disease and has increased among adolescents and young adults.

The American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium will feature presentations on oculofacial surgery innovations, social justice and diversity, and more.

A validation of the observer-reported outcome of the Growth Hormone Deficiency-Child Impact Measure found it valid and reliable to understand the impact of treatment with growth hormone therapy.

At baseline, patients with chronic thromboembolic pulmonary hypertension (CTEPH) had worse health-related quality of life (HRQOL) than patients with idiopathic pulmonary arterial hypertension (IPAH), but over time the scores were similar.

The higher waitlist mortality for liver transplant among children with hepatocellular carcinoma (HCC) compared with hepatoblastoma (HBL) indicates a need to improve prioritization for children with HCC.

Posters presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting analyzed patient and physician perspectives on blood transfusions in acute myeloid leukemia (AML).

Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.

Even compared with other patients with chronic diseases, patients with Fabry disease had a very poor quality of life.

Patients with axial spondyloarthritis treated with secukinumab achieved a reduction in spinal pain and improved disease activity measures early in treatment.

The counties in the United States with more social vulnerabilities had higher premature mortality related to cardiovascular diseases, such as heart disease, stroke, high blood pressure, and heart failure.

The incidence of chronic liver disease is expected to sharply rise by 2030, making it important to understand the factors that influence patient outcomes.

Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.

Mortality and liver-related complications increased with fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD).

At the fully in-person meeting of the Asembia 2021 Specialty Pharmacy Summit, held in Las Vegas, Nevada, attendees will get multiple sessions looking into the future of specialty pharmacy, as well as sessions on hot topics like telehealth and health equity.

Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib.

Two posters presented at AMCP Nexus 2021 review the high burden of social determinants of health (SDOH) on patients with serious mental illness.

Most patients with Fabry disease reported decreased physical and mental health-related quality of life (HRQOL) over 13 years of follow-up.

The fall meeting has multiple sessions on different aspects of health disparities and addressing drug costs, including 3 sessions on biosimilars.

Individuals who drink more than 3 cups of coffee a day had decreased liver stiffness.

People who receive organ transplants have an elevated risk of developing cancer, particularly lung cancer and non-Hodgkin lymphoma (NHL).

Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).

Maralixibat is the first treatment approved for cholestatic pruritus in patients with Alagille syndrome who are 1 year or older.

With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.

In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.

Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.

Patients who are treated with direct-acting antivirals to treat hepatitis C virus (HCV) are still at risk of developing hepatocellular carcinoma (HCC).

The advisory committee voted against COVID-19 vaccine booster shots for individuals 16 years and older, but unanimously voted for booster shots for people 65 years and older or who are at high risk of severe COVID-19.